Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib Consolidation in Stage III EGFR+ NSCLC
NCT05338619Phase 2Recruiting
- Sponsor
- Sung Yong Lee
- Start
- Jun 2022
- Primary completion
- Mar 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Sung Yong Lee. Started Jun 2022; status: recruiting.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05338619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338619.